Key result
Hypoalbuminemia linked to ~330% higher risk of ifosfamide encephalopathy during chemotherapy.
Why the study?
Ifosfamide encephalopathy is a potential side effect of ifosfamide chemotherapy with unclear prevalence and risk factors at a single center.
What are the risk factors for developing ifosfamide encephalopathy in patients receiving ifosfamide chemotherapy?
Population
237 patients receiving ifosfamide chemotherapy at Barnes-Jewish Hospital from 1995 to 2003
Comparison
Patients receiving ifosfamide who developed encephalopathy vs those who did not
Design
Retrospective cohort study
Authors
Loading...
Hypoalbuminemia may flag higher encephalopathy risk during ifosfamide therapy; leaves open whether correction alters incidence.
Cohort (n=237)
No
What are the risk factors for developing ifosfamide encephalopathy in patients receiving ifosfamide chemotherapy?
Odds Ratio: 4.3 (95% CI 2.26–8.3)
Hypoalbuminemia is a significant risk factor for ifosfamide encephalopathy, increasing the odds of development by 4.3 times.
David et al. (2005) conducted a cohort in Ifosfamide encephalopathy (n=237). Hypoalbuminemia vs. Normal serum albumin was evaluated on Development of encephalopathy (OR 4.3, 95% CI 2.26-8.3). Hypoalbuminemia was significantly associated with the development of ifosfamide encephalopathy (OR 4.3; 95% CI 2.26-8.3) among patients receiving chemotherapy.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: